23 results on '"C. Chapuzet"'
Search Results
2. Hydrogen Generation from α Radiolysis of Organic Materials in Transuranic Waste. Comparison Between Experimental Data and STORAGE Calculations
- Author
-
C. Chapuzet, V. Roux-Serret, S. Esnouf, F. Cochin, E. Bossé, A. Dannoux-Papin, and J. Blancher
- Subjects
Nuclear and High Energy Physics ,Materials science ,Transuranic waste ,Nuclear Energy and Engineering ,business.industry ,Nuclear engineering ,Radiolysis ,Alternative energy ,Condensed Matter Physics ,business ,Astrophysics::Galaxy Astrophysics ,Atomic energy commission ,Hydrogen production - Abstract
The Alternative Energies and Atomic Energy Commission and Orano have developed a modeling tool named the Simulation Tool Of RAdiolysis Gas Emission (STORAGE) for assessing gas generation of interme...
- Published
- 2021
3. Early symptomatic neurosyphilis and ocular syphilis: A comparative study between HIV-positive and HIV-negative patients
- Author
-
Vero Rasoldier, Luc Paris, Martine Pestel-Caron, M. Muraine, B. Bodaghi, François Caron, C. Chapuzet, J. Gueudry, Roland Tubiana, Eric Caumes, Hôpital Charles Nicolle [Rouen], Epidémiosurveillance de protozooses à transmission alimentaire et vectorielle (ESCAPE), Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Université de Reims Champagne-Ardenne (URCA), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), VILLIER, Venceslas, CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Université de Reims Champagne-Ardenne (URCA)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- Subjects
Adult ,Male ,medicine.medical_specialty ,Visual acuity ,Visual Acuity ,Human immunodeficiency virus (HIV) ,HIV Infections ,medicine.disease_cause ,Eye Infections, Bacterial ,Ocular syphilis ,Serology ,Uveitis ,Neurosyphilis ,Sexual and Gender Minorities ,03 medical and health sciences ,Cerebrospinal fluid ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Internal medicine ,HIV Seropositivity ,medicine ,Humans ,Meningitis ,Paresthesia ,Syphilis ,ocular syphilis ,0303 health sciences ,030306 microbiology ,business.industry ,Cranial Nerves ,HIV ,Middle Aged ,medicine.disease ,Anti-Bacterial Agents ,3. Good health ,Treatment Outcome ,Infectious Diseases ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Female ,medicine.symptom ,business - Abstract
International audience; Objectives: Since the 2000s, there has been an increase in prevalence of neurosyphilis (NS) and ocular syphilis (OS). As data about symptomatic NS/OS is limited, this study aims to assess the characteristics of symptomatic NS/OS, according to HIV status.Methods: We compared the clinical and biological presentation of early symptomatic NS/OS and its outcome in HIV-positive and HIV-negative patients.Results: Ninety-six patients (93% men, 49% HIV-positive) were included from 2000 to 2016 in two centers, with 67 (69%) having OS, 15 (16%) NS, and 14 (14%) both. HIV-positive patients were younger (P = 0.006) and more likely to be males having sex with males (P = 0.00048) or to have a history of syphilis (P = 0.01). Among 81 OS, there were 43 posterior uveitis (57%), and bilateral involvement was more common in HIV-positive patients (62% versus 38%, P = 0.045). Among 29 NS there were 21 cases of cranial nerve involvement (72%), seven meningitis (24%) and 11 paresthesia (38%). Involvement of the VIIIth cranial nerve was the most common (16 cases). Treponemal tests were more commonly found positive in cerebrospinal fluid in HIV-positive patients (88% versus 76%, P = 0.04). Visual acuity (VA) always improved after treatment (initial VA logMAR 0.8 ± 0.8 versus 0.1 ± 0.1 at 3 months), but 32% and 18% of the patients still had neurological or ocular impairment respectively six and 12 months after treatment. Non-treponemal serological reversion was observed in 43/50 patients (88%) at six months.Conclusion: HIV infection has no consequence on the outcome of NS and OS. Sequelae are common, emphasizing the importance of prevention, and screening, and questioning enhanced treatment.
- Published
- 2021
4. P3664Infective endocarditis after transcatheter aortic valve implantation, a comparison with endocarditis occurring in surgical aortic prosthesis and native aortic valve patients
- Author
-
Pierre-Yves Litzler, Christophe Tron, Arnaud Savouré, Hélène Eltchaninoff, C. Marchand, G. Avinee, M. Joulakian, C. Flouriot, C. Alarcon, Eric Durand, C. Chapuzet, and N. Frebourg
- Subjects
Aortic valve ,medicine.medical_specialty ,medicine.anatomical_structure ,Aortic prosthesis ,Transcatheter aortic ,business.industry ,medicine ,Endocarditis ,Cardiology and Cardiovascular Medicine ,business ,medicine.disease ,Surgery - Abstract
Background Infective endocarditis is rare but serious. Epidemiology is well known in standard population and surgical valve patients (Pts). The recent development of Transcatheter Aortic Valve Implantation (TAVI) raises new questions about endocarditis in this population. Purpose The aim of this study was to assess outcomes of endocarditis in TAVI Pts and to compare the results to surgical aortic valve (SV) owners and native aortic valve (NV) patients. Methods We included all patients hospitalized in our institution and presenting with endocarditis after TAVI between 2012 and 2018. We compared these patients to those discussed within the “endocarditis team” and presenting with endocarditis located on SV or on NV. Results A total of 34 TAVI Pts were included and compared to a population of 45 SV and 68 NV Pts. TAVI Pts were older (83.1±1.1 yrs, vs 73.3±1.7 and 66.0±1.7, respectively; p Conclusion Despite more frequent comorbidities, TAVI patients affected by infective endocarditis have the same mortality during the first year after diagnosis compared to SV and NV patients but are more often rehospitalized.
- Published
- 2019
5. Clinical presentation, aetiology and outcomes of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study
- Author
-
Habib G., Erba P. A., Iung B., Donal E., Cosyns B., Laroche C., Popescu B. A., Prendergast B., Tornos P., Sadeghpour A., Oliver L., Vaskelyte J. -J., Sow R., Axler O., Maggioni A. P., Lancellotti P, C P Gale, B Beleslin, A Budaj, O Chioncel, N Dagres, N Danchin, J Emberson, D Erlinge, M Glikson, A Gray, M Kayikcioglu, A P Maggioni, V K Nagy, A Nedoshivin, A-S Petronio, J Roos-Hesselink, L Wallentin, U Zeymer, G Habib, P Lancellotti, B Cosyns, E Donal, P Erba, B Iung, B A Popescu, B Prendergast, P Tornos, M Andarala, C Berle, A Brunel-Lebecq, E Fiorucci, C Laroche, V Missiamenou, C Taylor, N N Ali Tatar-Chentir, M Al-Mallah, M Astrom Aneq, G Athanassopoulos, L P Badano, S Benyoussef, E Calderon Aranda, N M Cardim, K-L Chan, I Cruz, T Edvardsen, G Goliasch, A Hagendorff, K Hristova, O Kamp, D-H Kang, W Kong, S Matskeplishvili, M Meshaal, M Mirocevic, A N Neskovic, M Pazdernik, E Plonska-Gosciniak, M Raissouni, R Ronderos, L E Sade, A Sadeghpour, A Sambola, S Sengupta, J Separovic-Hanzevacki, M Takeuchi, E Tucay, A C Tude Rodrigues, A Varga, J Vaskelyte, K Yamagata, K Yiangou, H Zaky, I Granada, M Mahia, S Ressi, F Nacinovich, A Iribarren, P Fernandez Oses, G Avegliano, E Filipini, R Obregon, M Bangher, J Dho, L Cartasegna, M L Plastino, V Novas, C Shigel, G Reyes, M De Santos, N Gastaldello, M Granillo Fernandez, M Potito, G Streitenberger, P Velazco, J H Casabé, C Cortes, E Guevara, F Salmo, M Seijo, F Weidinger, M Heger, R Brooks, C Stöllberger, C-Y Ho, L Perschy, L Puskas, C Binder, R Rosenhek, M Schneider, M-P Winter, E Hoffer, M Melissopoulou, E Lecoq, D Legrand, S Jacquet, M Massoz, L Pierard, S Marchetta, R Dulgheru, C D Emal, C Oury, S Droogmans, D Kerkhove, D Plein, L Soens, C Weytjens, A Motoc, B Roosens, I Lemoine, I Rodrigus, B Paelinck, B Amsel, P Unger, D Konopnicki, C Beauloye, A Pasquet, J L Vanoverschelde, S Pierard, D Vancraeynest, F Sinnaeve, J L Andrade, K Staszko, R Dos Santos Monteiro, M H Miglioranza, D L Shuha, M Alcantara, V Cravo, L Fazzio, A Felix, M Iso, C Musa, A P Siciliano, F Villaca Filho, A Rodrigues, F Vilela, J Braga, R Silva, D Rodrigues, L Silva, S Morhy, C Fischer, M Vieira, T Afonso, J Abreu, S N Falcao, V A Moises, A Gouvea, F J Mancuso, A C Souza, C Y Silva, G João, C S Abboud, R Bellio de Mattos Barretto, A Ramos, R Arnoni, J E Assef, D J Della Togna, D Le Bihan, L Miglioli, A P Romero Oliveira, R Tadeu Magro Kroll, D Cortez, C L Gelape, M D C Peirira Nunes, T C De Abreu Ferrari, K Hay, V Le, M Page, F Poulin, C Sauve, K Serri, C Mercure, J Beaudoin, P Pibarot, I A Sebag, L G Rudski, G Ricafort, B Barsic, V Krajinovic, M Vargovic, D Lovric, V Reskovic-Luksic, J Vincelj, S Jaksic Jurinjak, V Yiannikourides, M Ioannides, C Pofaides, V Masoura, J Pudich, A Linhart, M Siranec, J Marek, K Blechova, M Kamenik, R Pelouch, Z Coufal, M Mikulica, M Griva, E Jancova, M Mikulcova, M Taborsky, J Precek, M Jecmenova, J Latal, J Widimsky, T Butta, S Machacek, R Vancata, J Spinar, M Holicka, F Pow Chon Long, N Anzules, A Bajana Carpio, G Largacha, E Penaherrera, D Moreira, E Mahfouz, E Elsafty, A Soliman, Y Zayed, J Aboulenein, M Abdel-Hay, A Almaghraby, M Abdelnaby, M Ahmed, B Hammad, Y Saleh, H Zahran, O Elgebaly, A Saad, M Ali, A Zeid, R El Sharkawy, A Al Kholy, R Doss, D Osama, H Rizk, A Elmogy, M Mishriky, P Assayag, S El Hatimi, S Hubert, J-P Casalta, F Gouriet, F Arregle, S Cammilleri, L Tessonnier, A Riberi, E Botelho-Nevers, A Gagneux-Brunon, R Pierrard, C Tulane, S Campisi, J-F Fuzellier, M Detoc, T Mehalla, D Boutoille, A S Lecompte, M Lefebvre, S Pattier, O Al Habash, N Asseray-Madani, C Biron, J Brochard, J Caillon, C Cueff, T Le Tourneau, R Lecomte, M M Magali Michel, J Orain, S Delarue, M Le Bras, J-F Faucher, V Aboyans, A Beeharry, H Durox, M Lacoste, J Magne, D Mohty, A David, V Pradel, V Sierra, A Neykova, B Bettayeb, S Elkentaoui, B Tzvetkov, G Landry, C Strady, K Ainine, S Baumard, C Brasselet, C Tassigny, V Valente-Pires, M Lefranc, B Hoen, B Lefevre, E Curlier, C Callier, N Fourcade, Y Jobic, S Ansard, R Le Berre, F Le Ven, M-C Pouliquen, G Prat, P Le Roux, F Bouchart, A Savoure, C Alarcon, C Chapuzet, I Gueit, C Tribouilloy, Y Bohbot, F Peugnet, M Gun, X Duval, X Lescure, E Ilic-Habensus, N Sadoul, C Selton-Suty, F Alla, F Goehringer, O Huttin, E Chevalier, R Garcia, V Le Marcis, P Tattevin, E Flecher, M Revest, C Chirouze, K Bouiller, L Hustache-Mathieu, T Klopfenstein, J Moreau, D Fournier, A-S Brunel, P Lim, L Oliver, J Ternacle, A Moussafeur, P Chavanet, L Piroth, A Salmon-Rousseau, M Buisson, S Mahy, C Martins, S Gohier, O Axler, F Baumann, S Lebras, C Piper, D Guckel, J Börgermann, D Horstkotte, E Winkelmann, B Brockmeier, D Grey, G Nickenig, R Schueler, C Öztürk, E Stöhr, C Hamm, T Walther, R Brandt, A-C Frühauf, C T Hartung, C Hellner, C Wild, M Becker, S Hamada, W Kaestner, K Stangl, F Knebel, G Baldenhofer, A Brecht, H Dreger, C Isner, F Pfafflin, M Stegemann, R Zahn, B Fraiture, C Kilkowski, A-K Karcher, S Klinger, H Tolksdorf, D Tousoulis, C Aggeli, S Sideris, E Venieri, G Sarri, D Tsiapras, I Armenis, A Koutsiari, G Floros, C Grassos, S Dragasis, L Rallidis, C Varlamos, L Michalis, K Naka, A Bechlioulis, A Kotsia, L Lakkas, K Pappas, C Papadopoulos, S Kiokas, A Lioni, S Misailidou, J Barbetseas, M Bonou, C Kapelios, I Tomprou, K Zerva, A Manolis, E Hamodraka, D Athanasiou, G Haralambidis, H Samaras, L Poulimenos, A Nagy, A Bartykowszki, E Gara, K Mungulmare, R Kasliwal, M Bansal, S Ranjan, A Bhan, M Kyavar, M Maleki, F Noohi Bezanjani, A Alizadehasl, S Boudagh, A Ghavidel, P Moradnejad, H R Pasha, B Ghadrdoost, D Gilon, J Strahilevitz, M Wanounou, S Israel, C d'Agostino, P Colonna, L De Michele, F Fumarola, M Stante, N Marchionni, V Scheggi, B Alterini, S Del Pace, P Stefano, C Sparano, N Ruozi, R Tenaglia, D Muraru, U Limbruno, A Cresti, P Baratta, M Solari, C Giannattasio, A Moreo, B De Chiara, B Lopez Montero, F Musca, C A Orcese, F Panzeri, F Spano, C F Russo, O Alfieri, M De Bonis, S Chiappetta, B Del Forno, M Ripa, P Scarpellini, C Tassan Din, B Castiglioni, R Pasciuta, S Carletti, D Ferrara, M Guffanti, G Iaci, E Lapenna, T Nisi, C Oltolini, E Busnardo, U Pajoro, E Agricola, R Meneghin, D Schiavi, F Piscione, R Citro, R M Benvenga, L Greco, L Soriente, I Radano, C Prota, M Bellino, D Di Vece, F Santini, A Salsano, G M Olivieri, F Turrini, R Messora, S Tondi, A Olaru, V Agnoletto, L Grassi, C Leonardi, S Sansoni, S Del Ponte, G M Actis Dato, A De Martino, N Ohte, S Kikuchi, K Wakami, K Aonuma, Y Seo, T Ishizu, T Machino-Ohtsuka, M Yamamoto, N Iida, H Nakajima, Y Nakagawa, C Izumi, M Amano, M Miyake, K Takahashi, I Shiojima, Y Miyasaka, H Maeba, Y Suwa, N Taniguchi, S Tsujimoto, T Kitai, M Ota, S Yuda, S Sasaki, N Hagiwara, K Yamazaki, K Ashihara, K Arai, C Saitou, S Saitou, G Suzuki, Y Shibata, N Watanabe, S Nishino, K Ashikaga, N Kuriyama, K Mahara, T Okubo, H Fujimaki, H Shitan, H Yamamoto, K Abe, M Terada, S Takanashi, M Sata, H Yamada, K Kusunose, Y Saijo, H Seno, O Yuichiro, T Onishi, F Sera, S Nakatani, H Mizuno, K Sengoku, S W Park, K Eun Kyoung, L Ga Yeon, J-W Hwang, C Jin-Oh, S-J Park, L Sang-Chol, C Sung-A, S Y Jang, R Heo, S Lee, J-M Song, E Jung, J Plisiene, A Dambrauskaite, G Gruodyte, R Jonkaitiene, V Mizariene, J Atkocaityte, R Zvirblyte, R Sow, A Codreanu, T Staub, C Michaux, E C L De la Vega, L Jacobs-Orazi, C Mallia Azzopardi, R G Xuereb, T Piscopo, J Farrugia, M Fenech, E Pllaha, C Vella, D Borg, R Casha, L Grib, E Raevschi, A Grejdieru, D Kravcenco, E Prisacari, E Samohvalov, S Samohvalov, N Sceglova, E Panfile, L Cardaniuc, V Corcea, A Feodorovici, V Gaina, L Girbu, P Jimbei, G Balan, I Cardaniuc, I Benesco, V Marian, N Sumarga, B Bozovic, N Bulatovic, P Lakovic, L Music, R Budde, A Wahadat, T Gamela, T Meijers, J P Van Melle, V M Deursen, H J Crijns, S C Bekkers, E C Cheriex, M Gilbers, B L Kietselaer, C Knackstedt, R Lorusso, S Schalla, S A Streukens, S Chamuleau, M-J Cramer, A Teske, T Van der Spoel, A Wind, J Lokhorst, O Liesbek, H Van Heusden, W Tanis, I Van der Bilt, J Vriend, H De Lange-van Bruggen, E Karijodikoro, R Riezebos, E van Dongen, J Schoep, V Stolk, J T Offstad, J O Beitnes, T Helle-Valle, H Skulstad, R Skardal, N Qamar, S Furnaz, B Ahmed, M H Butt, M F Khanzada, T Saghir, A Wahid, T Hryniewiecki, P Szymanski, K Marzec, M Misztal-Ogonowska, W Kosmala, M Przewlocka-Kosmala, A Rojek, K Woznicka, J Zachwyc, A Lisowska, M Kaminska, J D Kasprzak, E Kowalczyk, D F Strzecka, P Wejner-Mik, M Trabulo, P Freitas, S Ranchordas, G Rodrigues, P Pinto, C Queiros, J Azevedo, L Marques, D Seabra, L Branco, M Cruz, A Galrinho, R Moreira, P Rio, A T Timoteo, M Selas, V Carmelo, B Duque Neves, H Pereira, A Guerra, A Marques, I Pintassilgo, M C Tomescu, N-M Trofenciuc, M Andor, A Bordejevic, H S Branea, F Caruntu, L A Velcean, A Mavrea, M F Onel, T Parvanescu, D Pop, A L Pop-Moldovan, M I Puticiu, L Cirin, I M Citu, C A Cotoraci, D Darabantiu, R Farcas, I Marincu, A Ionac, D Cozma, C Mornos, F Goanta, I Popescu, R Beyer, R Mada, R Rancea, R Tomoaia, H Rosianu, C Stanescu, Z Kobalava, J Karaulova, E Kotova, A Milto, A Pisaryuk, N Povalyaev, M Sorokina, J Alrahimi, A Elshiekh, A Jamiel, A Ahmed, N Attia, B Putnikovic, A Dimic, B Ivanovic, S Matic, D Trifunovic, J Petrovic, D Kosevic, I Stojanovic, I Petrovic, P Dabic, P Milojevic, I Srdanovic, S Susak, L Velicki, A Vulin, M Kovacevic, A Redzek, M Stefanovic, T C Yeo, W Kf Kong, K K Poh, I Vilacosta, C Ferrera, C Olmos, M Abd El-Nasser, F Calvo Iglesias, E Blanco-Gonzalez, M Bravo Amaro, E Lopez-Rodriguez, J Lugo Adan, A N Germinas, P Pazos-Lopez, M Pereira Loureiro, M T Perez, S Raposeiras-Roubin, S Rasheed Yas, M-M Suarez-Varela, F Vasallo Vidal, D Garcia-Dorado, N Fernandez-Hidalgo, T Gonzalez-Alujas, J Lozano, O Maisterra, N Pizzi, R Rios, A Bayes-Genis, L Pedro Botet, N Vallejo, C Llibre, L Mateu, R Nunez, D Quesada, E Berastegui, D Bosch Portell, J Aboal Vinas, X Albert Bertran, R Brugada Tarradellas, P Loma-Osorio Ricon, C Tiron de Llano, M A Arnau, A Bel, M Blanes, A Osa, M Anguita, F Carrasco, J C Castillo, J L Zamorano, J L Moya Mur, M Alvaro, C Fernandez-Golfin, J M Monteagudo, E Navas Elorza, M C Farinas Alvarez, J Aguero Balbin, J Zarauza, J F Gutierrez-Diez, C Arminanzas, F Arnaiz de Las Revillas, A Arnaiz Garcia, M Cobo Belaustegui, M Fernandez Sampedro, M Gutierrez Cuadra, L Garcia Cuello, C Gonzalez Rico, R Rodriguez-Alvarez, J Goikoetxea, M Montejo, J M Miro, M Almela, J Ambrosioni, A Moreno, E Quintana, E Sandoval, A Tellez, J M Tolosana, B Vidal, C Falces, D Fuster, C Garcia-de-la-Maria, M Hernandez-Meneses, J Llopis, F Marco, I Ruiz-Zamora, A Bardaji Ruiz, E Sanz Girgas, G Garcia-Pardo, M Guillen Marzo, A Rodriguez Oviedo, A Villares Jimenez, L Abid, R Hammami, S Kammoun, M S Mourali, F Mghaieth Zghal, M Ben Hlima, S Boudiche, S Ouali, L Zakhama, S Antit, I Slama, O Gulel, M Sahin, E Karacaglar, S Kucukoglu, O Cetinarslan, U Y Sinan, U Canpolat, B Mutlu, H Atas, R Dervishova, C Ileri, J Alhashmi, J Tahir, P Zarger, F Baslib, S Woldman, L Menezes, C Primus, R Uppal, I Bvekerwa, B Chandrasekaran, A Kopanska, J Chambers, J Hancock, J Klein, R Rajani, M P Ursi, S Cannata, R Dworakowski, A Fife, J Breeze, M Browne-Morgan, M Gunning, S Streather, F M Asch, M Zemedkun, B Alyavi, J Uzokov, G., Habib, P. A., Erba, B., Iung, E., Donal, B., Cosyn, C., Laroche, B. A., Popescu, B., Prendergast, P., Torno, A., Sadeghpour, L., Oliver, J. -J., Vaskelyte, R., Sow, O., Axler, A. P., Maggioni, P, Lancellotti, P Gale, C, Beleslin, B, Budaj, A, Chioncel, O, Dagres, N, Danchin, N, Emberson, J, Erlinge, D, Glikson, M, Gray, A, Kayikcioglu, M, P Maggioni, A, K Nagy, V, Nedoshivin, A, Petronio, A-S, Roos-Hesselink, J, Wallentin, L, Zeymer, U, Habib, G, Lancellotti, P, Cosyns, B, Donal, E, Erba, P, Iung, B, A Popescu, B, Prendergast, B, Tornos, P, Andarala, M, Berle, C, Brunel-Lebecq, A, Fiorucci, E, Laroche, C, Missiamenou, V, Taylor, C, N Ali Tatar-Chentir, N, Al-Mallah, M, Astrom Aneq, M, Athanassopoulos, G, P Badano, L, Benyoussef, S, Calderon Aranda, E, M Cardim, N, Chan, K-L, Cruz, I, Edvardsen, T, Goliasch, G, Hagendorff, A, Hristova, K, Kamp, O, Kang, D-H, Kong, W, Matskeplishvili, S, Meshaal, M, Mirocevic, M, N Neskovic, A, Pazdernik, M, Plonska-Gosciniak, E, Raissouni, M, Ronderos, R, E Sade, L, Sadeghpour, A, Sambola, A, Sengupta, S, Separovic-Hanzevacki, J, Takeuchi, M, Tucay, E, C Tude Rodrigues, A, Varga, A, Vaskelyte, J, Yamagata, K, Yiangou, K, Zaky, H, Granada, I, Mahia, M, Ressi, S, Nacinovich, F, Iribarren, A, Fernandez Oses, P, Avegliano, G, Filipini, E, Obregon, R, Bangher, M, Dho, J, Cartasegna, L, L Plastino, M, Novas, V, Shigel, C, Reyes, G, De Santos, M, Gastaldello, N, Granillo Fernandez, M, Potito, M, Streitenberger, G, Velazco, P, H Casabé, J, Cortes, C, Guevara, E, Salmo, F, Seijo, M, Weidinger, F, Heger, M, Brooks, R, Stöllberger, C, Ho, C-Y, Perschy, L, Puskas, L, Binder, C, Rosenhek, R, Schneider, M, Winter, M-P, Hoffer, E, Melissopoulou, M, Lecoq, E, Legrand, D, Jacquet, S, Massoz, M, Pierard, L, Marchetta, S, Dulgheru, R, D Emal, C, Oury, C, Droogmans, S, Kerkhove, D, Plein, D, Soens, L, Weytjens, C, Motoc, A, Roosens, B, Lemoine, I, Rodrigus, I, Paelinck, B, Amsel, B, Unger, P, Konopnicki, D, Beauloye, C, Pasquet, A, L Vanoverschelde, J, Pierard, S, Vancraeynest, D, Sinnaeve, F, L Andrade, J, Staszko, K, Dos Santos Monteiro, R, H Miglioranza, M, L Shuha, D, Alcantara, M, Cravo, V, Fazzio, L, Felix, A, Iso, M, Musa, C, P Siciliano, A, Villaca Filho, F, Rodrigues, A, Vilela, F, Braga, J, Silva, R, Rodrigues, D, Silva, L, Morhy, S, Fischer, C, Vieira, M, Afonso, T, Abreu, J, N Falcao, S, A Moises, V, Gouvea, A, J Mancuso, F, C Souza, A, Y Silva, C, João, G, S Abboud, C, Bellio de Mattos Barretto, R, Ramos, A, Arnoni, R, E Assef, J, J Della Togna, D, Le Bihan, D, Miglioli, L, P Romero Oliveira, A, Tadeu Magro Kroll, R, Cortez, D, L Gelape, C, C Peirira Nunes, M D, C De Abreu Ferrari, T, Hay, K, Le, V, Page, M, Poulin, F, Sauve, C, Serri, K, Mercure, C, Beaudoin, J, Pibarot, P, A Sebag, I, G Rudski, L, Ricafort, G, Barsic, B, Krajinovic, V, Vargovic, M, Lovric, D, Reskovic-Luksic, V, Vincelj, J, Jaksic Jurinjak, S, Yiannikourides, V, Ioannides, M, Pofaides, C, Masoura, V, Pudich, J, Linhart, A, Siranec, M, Marek, J, Blechova, K, Kamenik, M, Pelouch, R, Coufal, Z, Mikulica, M, Griva, M, Jancova, E, Mikulcova, M, Taborsky, M, Precek, J, Jecmenova, M, Latal, J, Widimsky, J, Butta, T, Machacek, S, Vancata, R, Spinar, J, Holicka, M, Pow Chon Long, F, Anzules, N, Bajana Carpio, A, Largacha, G, Penaherrera, E, Moreira, D, Mahfouz, E, Elsafty, E, Soliman, A, Zayed, Y, Aboulenein, J, Abdel-Hay, M, Almaghraby, A, Abdelnaby, M, Ahmed, M, Hammad, B, Saleh, Y, Zahran, H, Elgebaly, O, Saad, A, Ali, M, Zeid, A, El Sharkawy, R, Al Kholy, A, Doss, R, Osama, D, Rizk, H, Elmogy, A, Mishriky, M, Assayag, P, El Hatimi, S, Hubert, S, Casalta, J-P, Gouriet, F, Arregle, F, Cammilleri, S, Tessonnier, L, Riberi, A, Botelho-Nevers, E, Gagneux-Brunon, A, Pierrard, R, Tulane, C, Campisi, S, Fuzellier, J-F, Detoc, M, Mehalla, T, Boutoille, D, S Lecompte, A, Lefebvre, M, Pattier, S, Al Habash, O, Asseray-Madani, N, Biron, C, Brochard, J, Caillon, J, Cueff, C, Le Tourneau, T, Lecomte, R, M Magali Michel, M, Orain, J, Delarue, S, Le Bras, M, Faucher, J-F, Aboyans, V, Beeharry, A, Durox, H, Lacoste, M, Magne, J, Mohty, D, David, A, Pradel, V, Sierra, V, Neykova, A, Bettayeb, B, Elkentaoui, S, Tzvetkov, B, Landry, G, Strady, C, Ainine, K, Baumard, S, Brasselet, C, Tassigny, C, Valente-Pires, V, Lefranc, M, Hoen, B, Lefevre, B, Curlier, E, Callier, C, Fourcade, N, Jobic, Y, Ansard, S, Le Berre, R, Le Ven, F, Pouliquen, M-C, Prat, G, Le Roux, P, Bouchart, F, Savoure, A, Alarcon, C, Chapuzet, C, Gueit, I, Tribouilloy, C, Bohbot, Y, Peugnet, F, Gun, M, Duval, X, Lescure, X, Ilic-Habensus, E, Sadoul, N, Selton-Suty, C, Alla, F, Goehringer, F, Huttin, O, Chevalier, E, Garcia, R, Le Marcis, V, Tattevin, P, Flecher, E, Revest, M, Chirouze, C, Bouiller, K, Hustache-Mathieu, L, Klopfenstein, T, Moreau, J, Fournier, D, Brunel, A-S, Lim, P, Oliver, L, Ternacle, J, Moussafeur, A, Chavanet, P, Piroth, L, Salmon-Rousseau, A, Buisson, M, Mahy, S, Martins, C, Gohier, S, Axler, O, Baumann, F, Lebras, S, Piper, C, Guckel, D, Börgermann, J, Horstkotte, D, Winkelmann, E, Brockmeier, B, Grey, D, Nickenig, G, Schueler, R, Öztürk, C, Stöhr, E, Hamm, C, Walther, T, Brandt, R, Frühauf, A-C, T Hartung, C, Hellner, C, Wild, C, Becker, M, Hamada, S, Kaestner, W, Stangl, K, Knebel, F, Baldenhofer, G, Brecht, A, Dreger, H, Isner, C, Pfafflin, F, Stegemann, M, Zahn, R, Fraiture, B, Kilkowski, C, Karcher, A-K, Klinger, S, Tolksdorf, H, Tousoulis, D, Aggeli, C, Sideris, S, Venieri, E, Sarri, G, Tsiapras, D, Armenis, I, Koutsiari, A, Floros, G, Grassos, C, Dragasis, S, Rallidis, L, Varlamos, C, Michalis, L, Naka, K, Bechlioulis, A, Kotsia, A, Lakkas, L, Pappas, K, Papadopoulos, C, Kiokas, S, Lioni, A, Misailidou, S, Barbetseas, J, Bonou, M, Kapelios, C, Tomprou, I, Zerva, K, Manolis, A, Hamodraka, E, Athanasiou, D, Haralambidis, G, Samaras, H, Poulimenos, L, Nagy, A, Bartykowszki, A, Gara, E, Mungulmare, K, Kasliwal, R, Bansal, M, Ranjan, S, Bhan, A, Kyavar, M, Maleki, M, Noohi Bezanjani, F, Alizadehasl, A, Boudagh, S, Ghavidel, A, Moradnejad, P, R Pasha, H, Ghadrdoost, B, Gilon, D, Strahilevitz, J, Wanounou, M, Israel, S, D'Agostino, C, Colonna, P, De Michele, L, Fumarola, F, Stante, M, Marchionni, N, Scheggi, V, Alterini, B, Del Pace, S, Stefano, P, Sparano, C, Ruozi, N, Tenaglia, R, Muraru, D, Limbruno, U, Cresti, A, Baratta, P, Solari, M, Giannattasio, C, Moreo, A, De Chiara, B, Lopez Montero, B, Musca, F, A Orcese, C, Panzeri, F, Spano, F, F Russo, C, Alfieri, O, DE BONIS, Michele, Chiappetta, S, Del Forno, B, Ripa, M, Scarpellini, P, Tassan Din, C, Castiglioni, B, Pasciuta, R, Carletti, S, Ferrara, D, Guffanti, M, Iaci, G, Lapenna, E, Nisi, T, Oltolini, C, Busnardo, E, Pajoro, U, Agricola, E, Meneghin, R, Schiavi, D, Piscione, F, Citro, R, M Benvenga, R, Greco, L, Soriente, L, Radano, I, Prota, C, Bellino, M, Di Vece, D, Santini, F, Salsano, A, M Olivieri, G, Turrini, F, Messora, R, Tondi, S, Olaru, A, Agnoletto, V, Grassi, L, Leonardi, C, Sansoni, S, Del Ponte, S, M Actis Dato, G, De Martino, A, Ohte, N, Kikuchi, S, Wakami, K, Aonuma, K, Seo, Y, Ishizu, T, Machino-Ohtsuka, T, Yamamoto, M, Iida, N, Nakajima, H, Nakagawa, Y, Izumi, C, Amano, M, Miyake, M, Takahashi, K, Shiojima, I, Miyasaka, Y, Maeba, H, Suwa, Y, Taniguchi, N, Tsujimoto, S, Kitai, T, Ota, M, Yuda, S, Sasaki, S, Hagiwara, N, Yamazaki, K, Ashihara, K, Arai, K, Saitou, C, Saitou, S, Suzuki, G, Shibata, Y, Watanabe, N, Nishino, S, Ashikaga, K, Kuriyama, N, Mahara, K, Okubo, T, Fujimaki, H, Shitan, H, Yamamoto, H, Abe, K, Terada, M, Takanashi, S, Sata, M, Yamada, H, Kusunose, K, Saijo, Y, Seno, H, Yuichiro, O, Onishi, T, Sera, F, Nakatani, S, Mizuno, H, Sengoku, K, W Park, S, Eun Kyoung, K, Ga Yeon, L, Hwang, J-W, Jin-Oh, C, Park, S-J, Sang-Chol, L, Sung-A, C, Y Jang, S, Heo, R, Lee, S, Song, J-M, Jung, E, Plisiene, J, Dambrauskaite, A, Gruodyte, G, Jonkaitiene, R, Mizariene, V, Atkocaityte, J, Zvirblyte, R, Sow, R, Codreanu, A, Staub, T, Michaux, C, L De la Vega, E C, Jacobs-Orazi, L, Mallia Azzopardi, C, G Xuereb, R, Piscopo, T, Farrugia, J, Fenech, M, Pllaha, E, Vella, C, Borg, D, Casha, R, Grib, L, Raevschi, E, Grejdieru, A, Kravcenco, D, Prisacari, E, Samohvalov, E, Samohvalov, S, Sceglova, N, Panfile, E, Cardaniuc, L, Corcea, V, Feodorovici, A, Gaina, V, Girbu, L, Jimbei, P, Balan, G, Cardaniuc, I, Benesco, I, Marian, V, Sumarga, N, Bozovic, B, Bulatovic, N, Lakovic, P, Music, L, Budde, R, Wahadat, A, Gamela, T, Meijers, T, P Van Melle, J, M Deursen, V, J Crijns, H, C Bekkers, S, C Cheriex, E, Gilbers, M, L Kietselaer, B, Knackstedt, C, Lorusso, R, Schalla, S, A Streukens, S, Chamuleau, S, Cramer, M-J, Teske, A, Van der Spoel, T, Wind, A, Lokhorst, J, Liesbek, O, Van Heusden, H, Tanis, W, Van der Bilt, I, Vriend, J, De Lange-van Bruggen, H, Karijodikoro, E, Riezebos, R, van Dongen, E, Schoep, J, Stolk, V, T Offstad, J, O Beitnes, J, Helle-Valle, T, Skulstad, H, Skardal, R, Qamar, N, Furnaz, S, Ahmed, B, H Butt, M, F Khanzada, M, Saghir, T, Wahid, A, Hryniewiecki, T, Szymanski, P, Marzec, K, Misztal-Ogonowska, M, Kosmala, W, Przewlocka-Kosmala, M, Rojek, A, Woznicka, K, Zachwyc, J, Lisowska, A, Kaminska, M, D Kasprzak, J, Kowalczyk, E, F Strzecka, D, Wejner-Mik, P, Trabulo, M, Freitas, P, Ranchordas, S, Rodrigues, G, Pinto, P, Queiros, C, Azevedo, J, Marques, L, Seabra, D, Branco, L, Cruz, M, Galrinho, A, Moreira, R, Rio, P, T Timoteo, A, Selas, M, Carmelo, V, Duque Neves, B, Pereira, H, Guerra, A, Marques, A, Pintassilgo, I, C Tomescu, M, Trofenciuc, N-M, Andor, M, Bordejevic, A, S Branea, H, Caruntu, F, A Velcean, L, Mavrea, A, F Onel, M, Parvanescu, T, Pop, D, L Pop-Moldovan, A, I Puticiu, M, Cirin, L, M Citu, I, A Cotoraci, C, Darabantiu, D, Farcas, R, Marincu, I, Ionac, A, Cozma, D, Mornos, C, Goanta, F, Popescu, I, Beyer, R, Mada, R, Rancea, R, Tomoaia, R, Rosianu, H, Stanescu, C, Kobalava, Z, Karaulova, J, Kotova, E, Milto, A, Pisaryuk, A, Povalyaev, N, Sorokina, M, Alrahimi, J, Elshiekh, A, Jamiel, A, Ahmed, A, Attia, N, Putnikovic, B, Dimic, A, Ivanovic, B, Matic, S, Trifunovic, D, Petrovic, J, Kosevic, D, Stojanovic, I, Petrovic, I, Dabic, P, Milojevic, P, Srdanovic, I, Susak, S, Velicki, L, Vulin, A, Kovacevic, M, Redzek, A, Stefanovic, M, C Yeo, T, Kf Kong, W, K Poh, K, Vilacosta, I, Ferrera, C, Olmos, C, Abd El-Nasser, M, Calvo Iglesias, F, Blanco-Gonzalez, E, Bravo Amaro, M, Lopez-Rodriguez, E, Lugo Adan, J, N Germinas, A, Pazos-Lopez, P, Pereira Loureiro, M, T Perez, M, Raposeiras-Roubin, S, Rasheed Yas, S, Suarez-Varela, M-M, Vasallo Vidal, F, Garcia-Dorado, D, Fernandez-Hidalgo, N, Gonzalez-Alujas, T, Lozano, J, Maisterra, O, Pizzi, N, Rios, R, Bayes-Genis, A, Pedro Botet, L, Vallejo, N, Llibre, C, Mateu, L, Nunez, R, Quesada, D, Berastegui, E, Bosch Portell, D, Aboal Vinas, J, Albert Bertran, X, Brugada Tarradellas, R, Loma-Osorio Ricon, P, Tiron de Llano, C, A Arnau, M, Bel, A, Blanes, M, Osa, A, Anguita, M, Carrasco, F, C Castillo, J, L Zamorano, J, L Moya Mur, J, Alvaro, M, Fernandez-Golfin, C, M Monteagudo, J, Navas Elorza, E, C Farinas Alvarez, M, Aguero Balbin, J, Zarauza, J, F Gutierrez-Diez, J, Arminanzas, C, Arnaiz de Las Revillas, F, Arnaiz Garcia, A, Cobo Belaustegui, M, Fernandez Sampedro, M, Gutierrez Cuadra, M, Garcia Cuello, L, Gonzalez Rico, C, Rodriguez-Alvarez, R, Goikoetxea, J, Montejo, M, M Miro, J, Almela, M, Ambrosioni, J, Moreno, A, Quintana, E, Sandoval, E, Tellez, A, M Tolosana, J, Vidal, B, Falces, C, Fuster, D, Garcia-de-la-Maria, C, Hernandez-Meneses, M, Llopis, J, Marco, F, Ruiz-Zamora, I, Bardaji Ruiz, A, Sanz Girgas, E, Garcia-Pardo, G, Guillen Marzo, M, Rodriguez Oviedo, A, Villares Jimenez, A, Abid, L, Hammami, R, Kammoun, S, S Mourali, M, Mghaieth Zghal, F, Ben Hlima, M, Boudiche, S, Ouali, S, Zakhama, L, Antit, S, Slama, I, Gulel, O, Sahin, M, Karacaglar, E, Kucukoglu, S, Cetinarslan, O, Y Sinan, U, Canpolat, U, Mutlu, B, Atas, H, Dervishova, R, Ileri, C, Alhashmi, J, Tahir, J, Zarger, P, Baslib, F, Woldman, S, Menezes, L, Primus, C, Uppal, R, Bvekerwa, I, Chandrasekaran, B, Kopanska, A, Chambers, J, Hancock, J, Klein, J, Rajani, R, P Ursi, M, Cannata, S, Dworakowski, R, Fife, A, Breeze, J, Browne-Morgan, M, Gunning, M, Streather, S, M Asch, F, Zemedkun, M, Alyavi, B, Uzokov, J, Hôpital de la Timone [CHU - APHM] (TIMONE), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), University Medical Center Groningen [Groningen] (UMCG), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Université de Médecine Carol Davila, Guy's and St Thomas' Hospital [London], CHU Henri Mondor, Centre Hospitalier Universitaire de Liège (CHU-Liège), AstraZeneca, Bayer, Edwards Lifesciences, Servier, Abbott Vascular Int., Amgen Cardiovascular, Pfizer Alliance, Daiichi Sankyo Europe GmbH, Alliance Daiichi Sankyo Europe GmbH, Gedeon Richter Plc., Menarini Int. Op., Vifor, Boehringer Ingelheim, Boston Scientific Corporation, Bristol-Myers Squibb, Eli Lilly and Company, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service de pathologies cardiovasculaires intensives, UCL - (SLuc) Service de soins intensifs, Service de cardiologie, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), CIC - CHU Bichat, Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie et maladies vasculaires, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Oxford University Hospitals NHS Trust, University of Oxford [Oxford], Université Paris-Est Créteil Val-de-Marne - Faculté de médecine (UPEC Médecine), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université de Bordeaux (UB), Research Center [Associazione Nazionale Medici Cardiologi Ospedalieri] (ANMCO Research Center), Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO), Service de cardiologie [Liège], CHU de Liège-Domaine Universitaire du Sart Tilman, Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Exeter, Instituto Nacional de Tecnología Agropecuaria, Pergamino, Argentina, Laboratory of In Vivo Cellular and Molecular Imaging, Vrije Universiteit Brussel (VUB), Centre National de la Recherche Scientifique (CNRS), Division of Engineering and Applied Science, California Institute of Technology, California Institute of Technology (CALTECH), Departamento de Biologia de la Reproduccion, Universidad Autónoma Metropolitana Iztapalapa (UAMI), Universidade Federal de Itajubá, Departamento de Física [Coimbra] (DFC), Universidade de Coimbra [Coimbra], Section of Internal Medicine and Endocrine and Metabolic Sciences, Università degli Studi di Perugia (UNIPG), LIP-Coimbra & Department of Physics of the University of Coimbra, Service Hospitalier Frédéric Joliot (SHFJ), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Quebec Heart Institute/Laval Hospital, Université Laval [Québec] (ULaval)-Quebec Heart Institute, Institut Lavoisier de Versailles (ILV), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU AMU), CHU Saint-Etienne, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service des maladies infectieuses et tropicales [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Service de bactériologie et hygiène hospitalière [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Institut du thorax, Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des Maladies infectieuses et tropicales [CHU Limoges], CHU Limoges, Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Centre Hospitalier Universitaire de Reims (CHU Reims), Anesthésie et réanimation en chirurgie cardiaque [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Normandie Université (NU), Service des maladies infectieuses et tropicales [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Mécanismes physiologiques et conséquences des calcifications cardiovasculaires: rôle des remodelages cardiovasculaires et osseux, Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Cardiology [Ospedali del Tigullio], Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Cardiologie [CHRU Nancy], Service des maladies infectieuses et réanimation médicale, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Service de chirurgie thoracique cardiaque et vasculaire [Rennes], Laboratoire Chrono-environnement - CNRS - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), service de maladies infectieuses CHU J Minjoz Besancon, Hôpital Jean Minjoz, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Département d'infectiologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Virologie et pathogenèse virale (VPV), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Institució Catalana de Recerca i Estudis Avançats (ICREA), Institute for Advanced Studies in Basic Sciences, affiliation inconnue, Dipartamento di Fisica 'E.R. Caianiello', Università degli Studi di Salerno (UNISA), The University of Tokyo, Northern Research Station, Forestry Commission, University of North Carolina [Chapel Hill] (UNC), University of North Carolina System (UNC), Instituto de Plasmas e Fusão Nuclear [Lisboa] (IPFN), Instituto Superior Técnico, Universidade Técnica de Lisboa (IST), Instituto de Investigaciones Marinas (CSIC), Faculté des Sciences Pharmaceutiques, EA 4529, Laboratoire de Biochimie, Université Paris-Sud - Paris 11 (UP11), Istituto di Virologia Vegetale, Università degli studi di Torino (UNITO), Universidad Nacional Autónoma de México (UNAM), Service de Chirurgie Cardiovasculaire, University Hospital of Cruces, Geneva University Hospital (HUG), Institut Jean Le Rond d'Alembert (DALEMBERT), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Preventive Medicine Unit, University Hospital Joan XXIII, IISPV, Rovira and Virgili University, Popescu, B, Maggioni, A, Gale, C, Nagy, V, Petronio, A, Ali Tatar-Chentir, N, Badano, L, Cardim, N, Chan, K, Kang, D, Neskovic, A, Sade, L, Tude Rodrigues, A, Plastino, M, Casabe, J, Stollberger, C, Ho, C, Winter, M, Emal, C, Vanoverschelde, J, Andrade, J, Miglioranza, M, Shuha, D, Siciliano, A, Falcao, S, Moises, V, Mancuso, F, Souza, A, Silva, C, Joao, G, Abboud, C, Assef, J, Della Togna, D, Romero Oliveira, A, Gelape, C, Peirira Nunes, M, De Abreu Ferrari, T, Sebag, I, Rudski, L, Casalta, J, Fuzellier, J, Lecompte, A, Magali Michel, M, Faucher, J, Pouliquen, M, Brunel, A, Borgermann, J, Ozturk, C, Stohr, E, Fruhauf, A, Hartung, C, Karcher, A, Pasha, H, Orcese, C, Russo, C, De Bonis, M, Benvenga, R, Olivieri, G, Actis Dato, G, Park, S, Hwang, J, Jang, S, Song, J, De la Vega, E, Xuereb, R, Van Melle, J, Deursen, V, Crijns, H, Bekkers, S, Cheriex, E, Kietselaer, B, Streukens, S, Cramer, M, Offstad, J, Beitnes, J, Butt, M, Khanzada, M, Kasprzak, J, Strzecka, D, Timoteo, A, Tomescu, M, Trofenciuc, N, Branea, H, Velcean, L, Onel, M, Pop-Moldovan, A, Puticiu, M, Citu, I, Cotoraci, C, Yeo, T, Poh, K, Germinas, A, Perez, M, Suarez-Varela, M, Arnau, M, Castillo, J, Zamorano, J, Moya Mur, J, Monteagudo, J, Farinas Alvarez, M, Gutierrez-Diez, J, Miro, J, Tolosana, J, Mourali, M, Yasar, U, Ursi, M, Asch, F, Clinical sciences, Cardio-vascular diseases, Cardiology, Medical Imaging, Cardiovascular Centre (CVC), Service de médecine nucléaire [Marseille], Imagerie MOléculaire pour applications THéranostiques personnalisées (IMOTHEP), Institut FRESNEL (FRESNEL), Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS)- Hôpital de la Timone [CHU - APHM] (TIMONE), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), MGSOG Scientific staff, MUMC+: MA Cardiologie (9), Cardiologie, RS: Carim - H01 Clinical atrial fibrillation, RS: CARIM - R2.01 - Clinical atrial fibrillation, RS: CARIM - R3.11 - Imaging, Promovendi CD, Fysiologie, MUMC+: MA Med Staf Artsass CTC (9), RS: CARIM - R1.06 - Genetic Epidemiology and Genomics of cardiovascular diseases, MUMC+: MA Med Staf Spec Cardiologie (9), RS: Carim - H02 Cardiomyopathy, RS: CARIM - R2.02 - Cardiomyopathy, CTC, MUMC+: MA Med Staf Spec CTC (9), RS: Carim - V04 Surgical intervention, RS: CARIM - R2.12 - Surgical intervention, RS: FdR IC Aansprakelijkheid, Graduate School, ACS - Heart failure & arrhythmias, Radiotherapy, CCA - Imaging and biomarkers, CCA - Cancer Treatment and Quality of Life, and ACS - Atherosclerosis & ischemic syndromes
- Subjects
Male ,SURGERY ,Embolism ,Infective endocarditi ,Infective endocarditis ,Registry ,Valve disease ,030204 cardiovascular system & hematology ,0302 clinical medicine ,Africa, Northern ,Positron Emission Tomography Computed Tomography ,030212 general & internal medicine ,Hospital Mortality ,Prospective Studies ,Registries ,Prospective cohort study ,Abscess ,Aged, 80 and over ,medicine.diagnostic_test ,Middle Aged ,Staphylococcal Infections ,3. Good health ,Cardiac surgery ,Community-Acquired Infections ,Europe ,Treatment Outcome ,Positron emission tomography ,Echocardiography ,Heart Valve Prosthesis ,[SDV.IB]Life Sciences [q-bio]/Bioengineering ,Female ,ECHOCARDIOGRAPHY ,Cardiology and Cardiovascular Medicine ,Adult ,medicine.medical_specialty ,Asia ,Prosthesis-Related Infections ,DIAGNOSIS ,03 medical and health sciences ,Fluorodeoxyglucose F18 ,Internal medicine ,Streptococcal Infections ,medicine ,MANAGEMENT ,Journal Article ,Humans ,Aged ,business.industry ,EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY ,Endocarditis, Bacterial ,South America ,medicine.disease ,Heart failure ,Etiology ,Radiopharmaceuticals ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Enterococcus - Abstract
Aims The EURO-ENDO registry aimed to study the management and outcomes of patients with infective endocarditis (IE). Methods and results Prospective cohort of 3116 adult patients (2470 from Europe, 646 from non-ESC countries), admitted to 156 hospitals in 40 countries between January 2016 and March 2018 with a diagnosis of IE based on ESC 2015 diagnostic criteria. Clinical, biological, microbiological, and imaging [echocardiography, computed tomography (CT) scan, 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT)] data were collected. Infective endocarditis was native (NVE) in 1764 (56.6%) patients, prosthetic (PVIE) in 939 (30.1%), and device-related (CDRIE) in 308 (9.9%). Infective endocarditis was community-acquired in 2046 (65.66%) patients. Microorganisms involved were staphylococci in 1085 (44.1%) patients, oral streptococci in 304 (12.3%), enterococci in 390 (15.8%), and Streptococcus gallolyticus in 162 (6.6%). 18F-fluorodeoxyglucose positron emission tomography/computed tomography was performed in 518 (16.6%) patients and presented with cardiac uptake (major criterion) in 222 (42.9%) patients, with a better sensitivity in PVIE (66.8%) than in NVE (28.0%) and CDRIE (16.3%). Embolic events occurred in 20.6% of patients, and were significantly associated with tricuspid or pulmonary IE, presence of a vegetation and Staphylococcus aureus IE. According to ESC guidelines, cardiac surgery was indicated in 2160 (69.3%) patients, but finally performed in only 1596 (73.9%) of them. In-hospital death occurred in 532 (17.1%) patients and was more frequent in PVIE. Independent predictors of mortality were Charlson index, creatinine > 2 mg/dL, congestive heart failure, vegetation length > 10 mm, cerebral complications, abscess, and failure to undertake surgery when indicated. Conclusion Infective endocarditis is still a life-threatening disease with frequent lethal outcome despite profound changes in its clinical, microbiological, imaging, and therapeutic profiles.
- Published
- 2019
6. Endocardites infectieuses sur TAVI (Transcatheter Aortic Valve Implantation) versus sur valve prothétique et native aortique : pronostic à 1 an similaire malgré un terrain moins favorable selon une série prospective sur 9 ans
- Author
-
C. Chapuzet, François Caron, H. Eltchaninoff, C. Flouriot, and A. Savoure
- Subjects
Infectious Diseases - Abstract
Introduction Les EI/TAVI ont fait l’objet de description de cas mais de tres peu de series cliniques. Le but fut d’analyser 34 cas geres cette derniere decennie. Materiels et methodes Centre regional disposant d’un « endocarditis team » avec pour tous les cas d’EI/TAVI un suivi prospectif selon dossier structure. Inclusion de tous les cas d’EI aortique survenus depuis 2010, aussi bien sur TAVI, valve prothetique (VP) ou valve native (VN). Devenir a 1 an comme critere principal de jugement. Resultats Trente-quatre porteurs de valve TAVI ont ete inclus et compares a une population de 45 porteurs de valves prothetiques aortiques chirurgicales et 68 valves aortiques natives. Les patients porteurs de TAVI etaient plus âges avec une moyenne > 80 ans (83,1 ± 1,1 ans, vs 73,3 ± 1,7 et 66 ± 1,7, respectivement ; p 6 (6,2 ± 0,4, vs 5,6 ± 0,4 et 4,1 ± 0,3 ; p Les ETT etaient moins souvent positives dans le groupe TAVI (14,7 % contre 40 % sur les valves chirurgicales et 86,6 % sur les valves natives, p Les durees d’antibiotherapie (43,4 ± 5,1 jours pour le groupe TAVI, 40,6 ± 2,9 jours pour le groupe valve chirurgicale, et 42,3 ± 5,2 jours pour le groupe valve native, p = 0,934). Les complications cliniques etaient semblables entre les 3 groupes et la mortalite est comparable a 1 an (29,2 %, vs 36,4 et 29,7 % p = 0,730). Cependant, les porteurs de TAVI etaient plus frequemment re hospitalises a 1 an (41,2 % vs 26,7 % et 16,2 %, p = 0,02) dont moins de 15 % avaient beneficie d’une procedure invasive : extraction chirurgicale ou de pacemaker en 14,7 % vs 35,6 % et 42,6 %, p = 0,019, dont un seul porteur de TAVI avait eu un remplacement par une valve chirurgicale. Conclusion Comparer les endocardites de patients porteurs de TAVI aux endocardites de patients porteurs de valve aortique prothetique chirurgicale ou native, montre, chez les porteurs de TAVI une population nettement plus co morbide, mais a 1 an de suivi, un taux de complication comparable et ce, avec une duree d’antibiotherapie et une etiologie microbiologique similaire (streptocoque, environ 40 jours) entre les 3 groupes et a une exception pres, sans prise en charge chirurgicale complementaire dans le groupe TAVI, la meme mortalite. Ces patients sont cependant plus souvent re hospitalises a 1 an.
- Published
- 2019
7. Infective endocarditis after transcatheter aortic valve implantation. A comparison with endocarditis occurring in surgical aortic prosthesis and native aortic valve patients
- Author
-
M. Joulakian, C. Marchand, N. Frebourg, C. Chapuzet, Arnaud Savouré, C. Flouriot, Hélène Eltchaninoff, Christophe Tron, C. Alarcon, Pierre-Yves Litzler, Eric Durand, and G. Avinee
- Subjects
Aortic valve ,medicine.medical_specialty ,education.field_of_study ,Transcatheter aortic ,business.industry ,Population ,medicine.disease ,Surgery ,medicine.anatomical_structure ,Aortic prosthesis ,Native valve ,Infective endocarditis ,Epidemiology ,medicine ,Endocarditis ,Cardiology and Cardiovascular Medicine ,business ,education - Abstract
Introduction Infective endocarditis is rare but serious. Epidemiology is well known in standard population and surgical valve patients (Pts). The recent development of Transcatheter Aortic Valve Implantation (TAVI) raise new questions about endocarditis in this population. Objective To assess the epidemiology and mortality of endocarditis in TAVI Pts and to compare the results to surgical valve owners and native patients. Method We included all patients presenting with endocarditis after TAVI between 2010 and 2018 hospitalized in our institution. We compared these patients to those discussed within the “endocarditis team staff” and presenting with endocarditis located on surgical aortic prosthetic valve or on native aortic valve. Results A total of 34 TAVI Pts were included, and compared to a population of 45 surgical aortic prosthetic valve and 68 native Pts. TAVI Pts were older (83.1 ± 1.1 yrs, vs 73.3 ± 1.7 and 66.0 ± 1.7, respectively; P Conclusion TAVI patients affected by infective endocarditis, despite more comorbidities, have the same mortality at 1 year compared to prosthetic valve owners and patients with aortic endocarditis on native valve but are more often rehospitalized.
- Published
- 2019
8. Pseudo-uvéite sévère associée à l’utilisation de moxifloxacine
- Author
-
A Duncombe, Marc Muraine, Julie Gueudry, C. Chapuzet, I. Gueit, and N. Massy
- Subjects
Gynecology ,Ophthalmology ,medicine.medical_specialty ,business.industry ,medicine ,Drug adverse effect ,business ,Pigment dispersion - Abstract
Resume Introduction La moxifloxacine est un antibiotique de la classe des fluoroquinolones, commercialisee en France depuis 2002. Elle est principalement utilisee dans le traitement des sinusites bacteriennes et des exacerbations aigues de bronchites chroniques. Le but de cette etude est de rapporter un possible effet secondaire oculaire severe lors de l’utilisation de la moxifloxacine par voie generale. Patient et methodes Presentation du cas d’un patient ayant presente un tableau d’uveite aigue severe suite a l’utilisation par voie generale de moxifloxacine. Onze jours apres le debut du traitement par moxifloxacine, sont apparues de maniere concomitante et bilaterale une douleur oculaire, une dispersion pigmentaire et une transillumination irienne diffuse. Une hypertonie oculaire compliquait le tableau. Le bilan paraclinique effectue a la recherche d’autres etiologies de cette uveite s’est revele negatif en particulier la ponction de chambre anterieure a la recherche de l’ADN des virus HSV, VZV, CMV et EBV. Discussion Les uveites induites par les medicaments sont relativement rares. La relation entre traitement par fluoroquinolones par voie generale et uveite a ete consideree comme « possible » selon les criteres de l’Organisation mondiale de la sante, dans une recente analyse retrospective de 40 cas. La moxifloxacine etait suspecte dans 25 de ces cas. Le tableau de transillumination irienne et de dispersion pigmentaire semble assez specifique. Conclusion Il semble important que les prescripteurs de moxifloxacine et les ophtalmologistes soient informes de ce possible effet indesirable afin qu’ils puissent le prendre en charge et le declarer.
- Published
- 2013
9. Nosocomial transmission of measles: do we need extra precautions to avoid it?
- Author
-
C. Chefson-Girault, E. Lerebours, G. Savoye, F. Lefebvre, Jean-François Gehanno, V. Lemée, C. Chapuzet, Véronique Merle, H. Marini, I. Gueit, P. Czernichow, and F. Freymuth
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Infectious Diseases ,business.industry ,Nosocomial transmission ,medicine ,General Medicine ,medicine.disease ,Intensive care medicine ,business ,Measles - Published
- 2011
10. ENDO-07 - Teicoplanine versus schéma standard en traitement de relais des endocardites infectieuses à cocci à gram positif
- Author
-
V. Leguillou, A. Savoure, E. Fiaux, C. Chapuzet, François Caron, L. Damian, and Martine Pestel-Caron
- Subjects
Infectious Diseases - Published
- 2016
11. [Severe pseudouveitis associated with moxifloxacin therapy]
- Author
-
A, Duncombe, J, Gueudry, N, Massy, C, Chapuzet, I, Gueit, and M, Muraine
- Subjects
Male ,Uveitis ,Aza Compounds ,Moxifloxacin ,Quinolines ,Humans ,Middle Aged ,Sinusitis ,Respiratory Tract Infections ,Severity of Illness Index ,Anti-Bacterial Agents ,Fluoroquinolones - Abstract
Moxifloxacin is an antibiotic of the fluoroquinolone class, marketed in France since 2002. It is used primarily in the treatment of bacterial sinusitis and acute exacerbations of chronic bronchitis. The purpose of this study is to report a possible severe ocular side effect following the systemic use of moxifloxacin.Case report of a patient who presented with the appearance of a severe acute uveitis after being treated with systemic moxifloxacin. Eleven days after initiation of moxifloxacin treatment, the patient developed simultaneous bilateral eye pain, pigment dispersion and diffuse iris transillumination. This case was further complicated by ocular hypertension. Etiologic investigations for other causes of the uveitis were negative. In particular, an anterior chamber tap was performed and PCR for herpes viruses (HSV, VZV, EBV, CMV) was negative.Drug-induced uveitis is relatively rare. The relationship between systemic fluoroquinolone treatment and the occurrence of uveitis has been considered "possible", according to World Health Organization criteria, in a recent retrospective analysis of 40 case reports. Moxifloxacin was suspected in 25 of these cases. The presence of both iris transillumination and pigment dispersion appears specific to the uveitis in question.It appears that practitioners prescribing moxifloxacin and ophthalmologists should be informed of this possible adverse effect, so that it may be quickly recognized, managed and reported.
- Published
- 2012
12. Risk factors for prolonged treatment of lymph node tuberculosis
- Author
-
J-P, Lanoix, T, Guimard, N, Ettahar, A, Grannec, C, Flateau, C, Chapuzet, H, Bentayeb, P, Tattevin, and J-L, Schmit
- Subjects
Adult ,Aged, 80 and over ,Male ,Time Factors ,Adolescent ,Antitubercular Agents ,HIV Infections ,Middle Aged ,Tuberculosis, Lymph Node ,Drug Administration Schedule ,Young Adult ,Risk Factors ,Weight Loss ,Humans ,Tuberculosis ,Female ,Aged ,Follow-Up Studies ,Retrospective Studies - Abstract
Lymph node tuberculosis (LNTB) is the most frequent form of extra-pulmonary tuberculosis (TB). Randomised, controlled trials have convincingly demonstrated that 6 months of chemotherapy is sufficient for most drug-susceptible LNTB. We performed a retrospective, multicentric study from 1997 to 2010 to describe factors associated with prolonged anti-tuberculosis treatment in patients with LNTB. Of 126 patients diagnosed with LNTB, 22 (17.5%) were human immunodeficiency virus (HIV) infected. The median treatment duration was 9 months (interquartile range, 6-12). Treatment was significantly longer in patients with HIV (P0.01), additional sites of TB (P0.01) or weight loss (P = 0.04). Factors independently associated with excessively lengthy treatment were HIV co-infection and the presence of other TB foci.
- Published
- 2012
13. Une myélopathie par neurobilhraziose : une exception ?
- Author
-
A. Perez, Pierre Fréger, Stéphane Derrey, François Proust, F. Hammad, G. Perrod, and C. Chapuzet
- Subjects
Surgery ,Neurology (clinical) - Published
- 2011
14. Bacteraemia associated with multiple septic localizations caused by Klebsiella pneumoniae sequence type ST660.
- Author
-
Jauvain M, Carrer M, Palma F, Chapuzet C, Courat N, Heslan C, Pereyre S, Cazanave C, and Brisse S
- Subjects
- Humans, Male, Aged, 80 and over, Endophthalmitis microbiology, Endophthalmitis diagnosis, France, Endocarditis, Bacterial microbiology, Endocarditis, Bacterial diagnosis, Cerebral Hemorrhage microbiology, Klebsiella pneumoniae genetics, Klebsiella pneumoniae isolation & purification, Klebsiella pneumoniae classification, Klebsiella pneumoniae pathogenicity, Klebsiella Infections microbiology, Klebsiella Infections diagnosis, Bacteremia microbiology
- Abstract
We report a case of Klebsiella pneumoniae bacteraemia in an 80-year-old man in France with no history of travel to Asia, complicated by endogenous endophthalmitis, multiple cerebral microbleeds and hepatic microabscesses, associated with a Bentall endocarditis. Hypervirulence pathotype was suggested based on clinical picture, bacterial isolate genomic sequence and hypermucoidy. Interestingly, the isolate had the non-K1/K2-capsular serotype locus KL113-like, carried a KpVP-1-like virulence plasmid, and belonged to the emerging sublineage SL660 (comprising the sequence type ST660)., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
15. Early symptomatic neurosyphilis and ocular syphilis: A comparative study between HIV-positive and HIV-negative patients.
- Author
-
Rasoldier V, Gueudry J, Chapuzet C, Bodaghi B, Muraine M, Tubiana R, Paris L, Pestel-Caron M, Caron F, and Caumes E
- Subjects
- Adult, Anti-Bacterial Agents therapeutic use, Cranial Nerves pathology, Eye Infections, Bacterial drug therapy, Female, HIV Seropositivity epidemiology, Humans, Male, Meningitis epidemiology, Middle Aged, Neurosyphilis drug therapy, Paresthesia epidemiology, Sexual and Gender Minorities statistics & numerical data, Syphilis drug therapy, Treatment Outcome, Uveitis epidemiology, Visual Acuity, Eye Infections, Bacterial epidemiology, HIV Infections epidemiology, Neurosyphilis epidemiology, Syphilis epidemiology
- Abstract
Objectives: Since the 2000s, there has been an increase in prevalence of neurosyphilis (NS) and ocular syphilis (OS). As data about symptomatic NS/OS is limited, this study aims to assess the characteristics of symptomatic NS/OS, according to HIV status., Methods: We compared the clinical and biological presentation of early symptomatic NS/OS and its outcome in HIV-positive and HIV-negative patients., Results: Ninety-six patients (93% men, 49% HIV-positive) were included from 2000 to 2016 in two centers, with 67 (69%) having OS, 15 (16%) NS, and 14 (14%) both. HIV-positive patients were younger (P=0.006) and more likely to be males having sex with males (P=0.00048) or to have a history of syphilis (P=0.01). Among 81 OS, there were 43 posterior uveitis (57%), and bilateral involvement was more common in HIV-positive patients (62% versus 38%, P=0.045). Among 29 NS there were 21 cases of cranial nerve involvement (72%), seven meningitis (24%) and 11 paresthesia (38%). Involvement of the VIII
th cranial nerve was the most common (16 cases). Treponemal tests were more commonly found positive in cerebrospinal fluid in HIV-positive patients (88% versus 76%, P=0.04). Visual acuity (VA) always improved after treatment (initial VA logMAR 0.8±0.8 versus 0.1±0.1 at 3 months), but 32% and 18% of the patients still had neurological or ocular impairment respectively six and 12 months after treatment. Non-treponemal serological reversion was observed in 43/50 patients (88%) at six months., Conclusion: HIV infection has no consequence on the outcome of NS and OS. Sequelae are common, emphasizing the importance of prevention, and screening, and questioning enhanced treatment., (Copyright © 2020 Elsevier Masson SAS. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
16. MRI findings in a case of Lissauer form of neurosyphilis.
- Author
-
Faraut E, Wallon D, Gueit E, Chapuzet C, and Lefaucheur R
- Subjects
- Adult, Anti-Bacterial Agents therapeutic use, Brain diagnostic imaging, Brain drug effects, Humans, Male, Neurosyphilis drug therapy, Penicillin G therapeutic use, White Matter diagnostic imaging, White Matter drug effects, Magnetic Resonance Imaging, Neurosyphilis diagnostic imaging
- Published
- 2018
- Full Text
- View/download PDF
17. 18F-FDG PET/CT as a central tool in the shift from chronic Q fever to Coxiella burnetii persistent focalized infection: A consecutive case series.
- Author
-
Eldin C, Melenotte C, Million M, Cammilleri S, Sotto A, Elsendoorn A, Thuny F, Lepidi H, Roblot F, Weitten T, Assaad S, Bouaziz A, Chapuzet C, Gras G, Labussiere AS, Landais C, Longuet P, Masseau A, Mundler O, and Raoult D
- Subjects
- Adult, Aged, Bone Diseases, Infectious microbiology, Coxiella burnetii, Endocarditis microbiology, Female, Fluorodeoxyglucose F18, Humans, Immunoglobulins blood, Lymphadenitis microbiology, Male, Middle Aged, Pneumonia, Bacterial diagnostic imaging, Pneumonia, Bacterial microbiology, Prosthesis-Related Infections microbiology, Q Fever blood, Radiopharmaceuticals, Retrospective Studies, Vascular Diseases microbiology, Bone Diseases, Infectious diagnostic imaging, Endocarditis diagnostic imaging, Lymphadenitis diagnostic imaging, Positron Emission Tomography Computed Tomography, Prosthesis-Related Infections diagnostic imaging, Q Fever diagnostic imaging, Vascular Diseases diagnostic imaging
- Abstract
Because Q fever is mostly diagnosed serologically, localizing a persistent focus of Coxiella burnetii infection can be challenging. F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) could be an interesting tool in this context.We performed a retrospective study on patients diagnosed with C burnetii infection, who had undergone F-FDG PET/CT between 2009 and 2015. When positive F-FDG PET/CT results were obtained, we tried to determine if it changed the previous diagnosis by discovering or confirming a suspected focus of C burnetii infection.One hundred sixty-seven patients benefited from F-FDG PET/CT. The most frequent clinical subgroup before F-FDG PET/CT was patients with no identified focus of infection, despite high IgG1 serological titers (34%). For 59% (n = 99) of patients, a hypermetabolic focus was identified. For 62 patients (62.6%), the positive F-FDG PET/CT allowed the diagnosis to be changed. For 24 of them, (38.7%), a previously unsuspected focus of infection was discovered. Forty-two (42%) positive patients had more than 1 hypermetabolic focus. We observed 21 valvular foci, 34 vascular foci, and a high proportion of osteoarticular localizations (n = 21). We also observed lymphadenitis (n = 27), bone marrow hypermetabolism (n = 11), and 9 pulmonary localizations.We confirmed thatF-FDG PET/CT is a central tool in the diagnosis of C burnetii focalized persistent infection. We proposed new diagnostic scores for 2 main clinical entities identified using F-FDG PET/CT: osteoarticular persistent infections and lymphadenitis.
- Published
- 2016
- Full Text
- View/download PDF
18. Association of dolutegravir and rilpivirine, enhanced by foscarnet induction, in effective salvage antiretroviral therapy.
- Author
-
Leporrier J, Etienne M, Chapuzet C, Peytavin G, Bord S, Borsa-Lebas F, Caron F, Plantier JC, and Mourez T
- Subjects
- Adult, Antiretroviral Therapy, Highly Active, Drug Resistance, Viral, HIV Integrase Inhibitors therapeutic use, HIV-1 drug effects, Humans, Infectious Disease Transmission, Vertical, Male, Oxazines, Piperazines, Pyridones, Reverse Transcriptase Inhibitors therapeutic use, Rilpivirine, Salvage Therapy methods, Young Adult, Anti-HIV Agents therapeutic use, Foscarnet therapeutic use, HIV Infections drug therapy, Heterocyclic Compounds, 3-Ring therapeutic use, Nitriles therapeutic use, Pyrimidines therapeutic use
- Abstract
We report the case of a multi-experienced patient, infected with an HIV-1 strain, with selected multiple resistance mutations. We designed a novel well-tolerated and effective rescue treatment including dolutegravir, rilpivirine, and foscarnet, allowing a 60-week sustained virological response for the first time in 23 years of HIV infection., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
19. [Severe pseudouveitis associated with moxifloxacin therapy].
- Author
-
Duncombe A, Gueudry J, Massy N, Chapuzet C, Gueit I, and Muraine M
- Subjects
- Anti-Bacterial Agents therapeutic use, Aza Compounds therapeutic use, Fluoroquinolones, Humans, Male, Middle Aged, Moxifloxacin, Quinolines therapeutic use, Respiratory Tract Infections drug therapy, Severity of Illness Index, Sinusitis drug therapy, Uveitis diagnosis, Anti-Bacterial Agents adverse effects, Aza Compounds adverse effects, Quinolines adverse effects, Uveitis chemically induced
- Abstract
Introduction: Moxifloxacin is an antibiotic of the fluoroquinolone class, marketed in France since 2002. It is used primarily in the treatment of bacterial sinusitis and acute exacerbations of chronic bronchitis. The purpose of this study is to report a possible severe ocular side effect following the systemic use of moxifloxacin., Patient and Methods: Case report of a patient who presented with the appearance of a severe acute uveitis after being treated with systemic moxifloxacin. Eleven days after initiation of moxifloxacin treatment, the patient developed simultaneous bilateral eye pain, pigment dispersion and diffuse iris transillumination. This case was further complicated by ocular hypertension. Etiologic investigations for other causes of the uveitis were negative. In particular, an anterior chamber tap was performed and PCR for herpes viruses (HSV, VZV, EBV, CMV) was negative., Discussion: Drug-induced uveitis is relatively rare. The relationship between systemic fluoroquinolone treatment and the occurrence of uveitis has been considered "possible", according to World Health Organization criteria, in a recent retrospective analysis of 40 case reports. Moxifloxacin was suspected in 25 of these cases. The presence of both iris transillumination and pigment dispersion appears specific to the uveitis in question., Conclusion: It appears that practitioners prescribing moxifloxacin and ophthalmologists should be informed of this possible adverse effect, so that it may be quickly recognized, managed and reported., (Copyright © 2012 Elsevier Masson SAS. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
20. Post-streptococcal scleritis: corticosteroids avoid visual acuity loss.
- Author
-
Etienne M, Gueudry J, Chapuzet C, Sabatier M, Muraine M, and Caron F
- Subjects
- Aged, Eye pathology, Female, Humans, Immunosuppressive Agents therapeutic use, Streptococcus pyogenes isolation & purification, Vision Disorders microbiology, Visual Acuity, Adrenal Cortex Hormones therapeutic use, Eye Infections, Bacterial complications, Scleritis drug therapy, Scleritis microbiology, Streptococcal Infections complications, Vision Disorders prevention & control
- Published
- 2012
- Full Text
- View/download PDF
21. Risk factors for prolonged treatment of lymph node tuberculosis.
- Author
-
Lanoix JP, Guimard T, Ettahar N, Grannec A, Flateau C, Chapuzet C, Bentayeb H, Tattevin P, and Schmit JL
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antitubercular Agents administration & dosage, Drug Administration Schedule, Female, Follow-Up Studies, HIV Infections epidemiology, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Time Factors, Tuberculosis epidemiology, Tuberculosis physiopathology, Weight Loss, Young Adult, Antitubercular Agents therapeutic use, HIV Infections complications, Tuberculosis, Lymph Node drug therapy
- Abstract
Lymph node tuberculosis (LNTB) is the most frequent form of extra-pulmonary tuberculosis (TB). Randomised, controlled trials have convincingly demonstrated that 6 months of chemotherapy is sufficient for most drug-susceptible LNTB. We performed a retrospective, multicentric study from 1997 to 2010 to describe factors associated with prolonged anti-tuberculosis treatment in patients with LNTB. Of 126 patients diagnosed with LNTB, 22 (17.5%) were human immunodeficiency virus (HIV) infected. The median treatment duration was 9 months (interquartile range, 6-12). Treatment was significantly longer in patients with HIV (P < 0.01), additional sites of TB (P < 0.01) or weight loss (P = 0.04). Factors independently associated with excessively lengthy treatment were HIV co-infection and the presence of other TB foci.
- Published
- 2012
- Full Text
- View/download PDF
22. Nosocomial transmission of measles: do we need extra precautions to avoid it?
- Author
-
Lefebvre F, Merle V, Savoye G, Lemée V, Chapuzet C, Marini H, Géhanno JF, Chefson-Girault C, Gueit I, Freymuth F, Lerebours E, and Czernichow P
- Subjects
- Adult, Cross Infection prevention & control, Cross Infection virology, Fatal Outcome, Female, France epidemiology, Gastroenterology, Genotype, Hospital Units, Hospitals, University, Humans, Infection Control methods, Male, Measles virology, Measles virus classification, Measles virus isolation & purification, Polymerase Chain Reaction methods, Young Adult, Cross Infection transmission, Measles prevention & control, Measles transmission, Measles virus genetics
- Published
- 2011
- Full Text
- View/download PDF
23. Should blood cultures be performed for patients with acute prostatitis?
- Author
-
Etienne M, Pestel-Caron M, Chapuzet C, Bourgeois I, Chavanet P, and Caron F
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Bacteremia microbiology, Bacteria classification, Humans, Male, Middle Aged, Prognosis, Prostatitis microbiology, Young Adult, Bacteremia diagnosis, Bacteria isolation & purification, Blood microbiology, Prostatitis complications, Prostatitis diagnosis
- Abstract
The diagnostic and prognostic values of blood cultures (BC) for 347 acute prostatitis inpatients were evaluated. BC were positive for 21% of patients and contributed to the microbiological diagnosis for 5%. Fever duration, length of hospitalization, use of an antibiotic combination, duration of antibiotic use, and urine bacterial titers increased when BC were positive.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.